Select therapeutic use:

CHF and arrhythmias:

Indications for: Acebutolol

Ventricular arrhythmias.

Adult Dosage:

Initially 200mg twice a day. Usual range: 600mg–1.2g daily.

Children Dosage:

Not established.

Acebutolol Contraindications:

Severe bradycardia. 2nd- or 3rd-degree AV block. Overt heart failure. Cardiogenic shock.

Acebutolol Warnings/Precautions:

Bronchospastic disease. Ischemic heart disease or failure. Renal or hepatic dysfunction. Diabetes. Hyperthyroidism. Vascular insufficiency. Surgery. Avoid abrupt cessation. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Acebutolol Classification:

Cardioselective beta-blocker.

Acebutolol Interactions:

May potentiate hypotension with prazosin, reserpine, other catecholamine-depleting drugs. Antagonized by NSAIDs. May increase cardiac effects of verapamil, digitalis. Avoid α-adrenergic agonists. May block epinephrine.

Adverse Reactions:

Fatigue, dizziness, headache, GI upset, dyspnea, dysuria, insomnia, rash, myalgia, rhinitis, abnormal vision, hypotension, bradycardia, heart failure or block, bronchospasm, elevated ANA titers.

Note:

Formerly known under the brand name Sectral.

Metabolism:

The major metabolite, an N-acetyl derivative (diacetolol), is pharmacologically active. This metabolite is equipotent to acebutolol and in cats is more cardioselective than acebutolol; therefore, this first-pass phenomenon does not attenuate the therapeutic effect of acebutolol. 

Drug Elimination:

The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours. Elimination via renal excretion is approximately 30% to 40% and by nonrenal mechanisms 50% to 60%, which includes excretion into the bile and direct passage through the intestinal wall.

How Supplied:

Contact supplier

Hypertension:

Indications for: Acebutolol

Hypertension.

Adult Dosage:

Initially 400mg daily in 1–2 divided doses. Usual range: 200–800mg daily; max 1.2g/day in 2 divided doses.

Children Dosage:

Not established.

Acebutolol Contraindications:

Severe bradycardia. 2nd- or 3rd-degree AV block. Overt heart failure. Cardiogenic shock.

Acebutolol Warnings/Precautions:

Bronchospastic disease. Ischemic heart disease or failure. Renal or hepatic dysfunction. Diabetes. Hyperthyroidism. Vascular insufficiency. Surgery. Avoid abrupt cessation. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Acebutolol Classification:

Cardioselective beta-blocker.

Acebutolol Interactions:

May potentiate hypotension with prazosin, reserpine, other catecholamine-depleting drugs. Antagonized by NSAIDs. May increase cardiac effects of verapamil, digitalis. Avoid α-adrenergic agonists. May block epinephrine.

Adverse Reactions:

Fatigue, dizziness, headache, GI upset, dyspnea, dysuria, insomnia, rash, myalgia, rhinitis, abnormal vision, hypotension, bradycardia, heart failure or block, bronchospasm, elevated ANA titers.

Note:

Formerly known under the brand name Sectral.

Metabolism:

The major metabolite, an N-acetyl derivative (diacetolol), is pharmacologically active. This metabolite is equipotent to acebutolol and in cats is more cardioselective than acebutolol; therefore, this first-pass phenomenon does not attenuate the therapeutic effect of acebutolol. 

Drug Elimination:

The plasma elimination half-life of acebutolol is approximately 3 to 4 hours, while that of its metabolite, diacetolol, is 8 to 13 hours. Elimination via renal excretion is approximately 30% to 40% and by nonrenal mechanisms 50% to 60%, which includes excretion into the bile and direct passage through the intestinal wall.

How Supplied:

Contact supplier